Market News

Spectrum Pharma (NASDAQ:SPPI) Plunges After Poziotinib Evidence is Questioned

Shares Spectrum Pharmaceuticals (NASDAQ:SPPI) are plunging in today’s trading after scientists from the U.S. Food and Drug Administration (FDA) raised concerns over the data shared by the company for poziotinib for the treatment of non-small cell lung cancer (NSCLC).

While the meeting of the advisory committee is scheduled for later this week, scientists from the regulator have flagged a low overall response rate as indicated by the data.

Moreover, concerns remain about dosage optimization and the safety profile of the drug as well.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More